Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 5, 2006, Pages 594-598

  Kragt, J J ^a   Van Der Linden, Fah ^a   Nielsen, J M ^a   Uitdehaag, B M J ^a   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

9HPT; Clinical scale; GNDS; MSFC; Multiple sclerosis; T25FW

Indexed keywords

ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DATA BASE; DISEASE EXACERBATION; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; LEG DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT SELECTION; SCORING SYSTEM; COMPARATIVE STUDY; HEARING; MIDDLE AGED; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; STATISTICS; WALKING;

ADULT; AUDITORY PERCEPTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; WALKING;

EID: 34250660553     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070768     Document Type: Article

References (15)

1. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58: 1294-96.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
3. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
4. Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419-24.
5. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997; 48: 817-21.
6. Goodman AD. Phase 2 trial of fampridine-SR in multiple sclerosis. Mult Scler 2004; 10: S273.
7. Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, et al. Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1998; 4: 480-86.
8. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 2000; 6: 286-90.
9. Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, et al. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 2000; 55: 1901 -903.
10. Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 55-60.
11. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999; 5: 223-33.
12. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
13. Hoogervorst EL, van Winsen LM, Eikelenboom MJ, Kalkers NF, Uitdehaag BM, Polman CH. Comparisons of patient self-report, neurologic examination, and functional impairment in MS. Neurology 2001; 56: 934-37.
14. Kalkers NF, de Groot V, Lazeron RH, Killestein J, Ader HJ, Barkhof F, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology 2000; 54: 1233-39.
15. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-73.